Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.42 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18185064 | 0.84 | TDP1 (0.42) | TDP1ALDH1A1MAPTMAPK1POLB | |
| SCHEMBL18185028 | 0.83 | TDP1 (0.41) | TDP1ALDH1A1MAPTMAPK1POLB | |
| SCHEMBL18185008 | 0.83 | MAPT (0.42) | TDP1ALDH1A1MAPTMAPK1POLB | |
| SCHEMBL18185021 | 0.81 | ALDH1A1 (0.40) | TDP1ALDH1A1MAPTMAPK1POLB | |
| SCHEMBL18184998 | 0.81 | TSHR (0.55) | TDP1ALDH1A1MAPTMAPK1POLB | |
| SCHEMBL3959736 | 0.81 | TDP1 (0.48) | TDP1ALDH1A1MAPTMAPK1POLB | |
| SCHEMBL18184974 | 0.80 | TDP1 (0.48) | TDP1ALDH1A1MAPTMAPK1SMN1; SMN2 | |
| SCHEMBL18185050 | 0.80 | ALDH1A1 (0.61) | TDP1ALDH1A1MAPTMAPK1SMN1; SMN2 | |
| SCHEMBL18185034 | 0.80 | LMNA (0.48) | TDP1ALDH1A1MAPTMAPK1POLB | |
| SCHEMBL18184989 | 0.80 | TDP1 (0.44) | TDP1ALDH1A1MAPTMAPK1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630516-B2 | Compounds | NRG THERAPEUTICS LTD. (GB) | 2026-05-19 | — | — | US | disclosed |
| EP-4208442-B1 | MPTP INHIBITORS | NRG THERAPEUTICS LTD (GB) | 2025-10-22 | — | — | EP | disclosed |
| US-20250179028-A1 | ACRYLAMIDE COMPOUNDS | NRG THERAPEUTICS LTD (GB) | 2025-06-05 | — | — | US | disclosed |
| EP-4486721-A1 | ACRYLAMIDE COMPOUNDS | NRG Therapeutics LTD (GB) | 2025-01-08 | — | — | EP | disclosed |
| CN-118804911-A | Acrylamide compound | NRG治疗有限公司 | 2024-10-18 | — | — | CN | disclosed |
| US-20240067614-A1 | NOVEL COMPOUNDS | NRG THERAPEUTICS LTD. (GB) | 2024-02-29 | — | — | US | disclosed |
| US-20240067614-A1 | NOVEL COMPOUNDS | NRG THERAPEUTICS LTD. (GB) | 2024-02-29 | — | — | US | disclosed |
| US-20240067614-A1 | NOVEL COMPOUNDS | NRG THERAPEUTICS LTD. (GB) | 2024-02-29 | — | — | US | disclosed |
| WO-2023166303-A1 | ACRYLAMIDE COMPOUNDS | NRG THERAPEUTICS LTD (GB) | 2023-09-07 | — | — | WO | disclosed |
| EP-4208442-A1 | NOVEL COMPOUNDS | NRG Therapeutics LTD (GB) | 2023-07-12 | — | — | EP | disclosed |
| CN-116096705-A | Novel compounds | NRG治疗有限公司 | 2023-05-09 | — | — | CN | disclosed |
| WO-2022049376-A1 | NOVEL COMPOUNDS | NRG THERAPEUTICS LTD (GB) | 2022-03-10 | — | — | WO | disclosed |
| EP-3088382-B1 | METHOD FOR PRODUCING NITRO COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2018-07-11 | — | — | EP | disclosed |
| US-9561998-B2 | Method for producing nitro compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-02-07 | — | — | US | disclosed |
| US-20160318846-A1 | METHOD FOR PRODUCING NITRO COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-11-03 | — | — | US | disclosed |
| EP-3088382-A1 | METHOD FOR PRODUCING NITRO COMPOUND | Sumitomo Chemical Company Limited (JP) | 2016-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318846-A1 | METHOD FOR PRODUCING NITRO COMPOUND | NOS1, NOS3, NOS2 | TDP1 3246/4885ALDH1A1 2305/4885MAPT 4455/4885 |
| US-12630516-B2 | Compounds | CYP4B1, CYP1B1, NR4A1 | TDP1 3531/4885ALDH1A1 87/4885MAPT 2453/4885 |
| US-20240067614-A1 | NOVEL COMPOUNDS | CYP11B1, CYP11B2, CXCR2 | TDP1 3648/4885ALDH1A1 478/4885MAPT 2596/4885 |
| US-20250179028-A1 | ACRYLAMIDE COMPOUNDS | ACR, CCNI, FANCI | TDP1 607/4885ALDH1A1 63/4885MAPT 1371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.